<?xml version="1.0" encoding="UTF-8"?>
<ref id="b71-etm-0-0-09142">
 <label>71</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lassaunière</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Frische</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Harboe</surname>
    <given-names>ZB</given-names>
   </name>
   <name>
    <surname>Nielsen</surname>
    <given-names>AC</given-names>
   </name>
   <name>
    <surname>Fomsgaard</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Krogfelt</surname>
    <given-names>KA</given-names>
   </name>
   <name>
    <surname>Jørgensen</surname>
    <given-names>CS</given-names>
   </name>
  </person-group>
  <comment>Evaluation of nine commercial SARS-CoV-2 immunoassays. Available at: 
   <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/medrxiv/early/2020/02/25/2020.02.22.20026617.full.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.medrxiv.org/content/medrxiv/early/2020/02/25/2020.02.22.20026617.full.pdf</ext-link>.
  </comment>
 </element-citation>
</ref>
